TAVR an Expanding Option for Patients with Aortic Valve Disease

Transcatheter aortic valve replacement (TAVR) is widening its reach as new valves reach the market and a broader pool of patients

Published: November 10, 2014

In the three years since the U.S. Food and Drug Administration (FDA) approved the first artificial valve for use in transcatheter aortic valve replacement (TAVR), two new valves have also been approved, and more types of patients are being considered for this increasingly common treatment.